TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pharmacokinetics of SK 0403
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Epicardial Fat Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of time spent in the hypoglycemic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of women who have post-removal complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of implants that are successfully removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of Ad26.RSV.preF (shedding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of PICO 7Y NPWT system within 7 days of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of the PICO7Y NPWT system through number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Axial score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients with clear or minimal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in PCWP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Episodes of Grade 3-4 Non Infectious, Non-dermatological or Non-neurological Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of Any Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3-4 Dermatological Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of Grade 2-3 Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients undergoing serial core biopsies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of micturition frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biochemical pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Heavy proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients With Hyperglycemia in the ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With Persistent Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cessation of Potentially Inappropriate Medications (PIMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of the graft
Endpoint domain: Mortality/survival
Primary endpoint: Pain Catastrophization Scale (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survival of device
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in OSDI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pleural Pressure (Pes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of CMR Imaging for detection of LAA thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Conduct Problem subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric mean time to parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: development of preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: improvement in NYHA class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in distance covered in the 6-minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of urinary tract infection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Public Speaking Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: resolution of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Experiencing ≥Grade 3 Severity in Laboratory Parameters (Hematology)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Clinically Significant Laboratory Parameters (Clinical Chemistry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of IMCgp100 Administered Weekly (Dose Escalation Part)
Endpoint domain: Physiological/clinical
Primary endpoint: SF12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Oxford Knee
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KSCRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Number of Days of Combustible and Noncombustible Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Train of four measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder status at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG frequency bands during spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Color matching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Whole Blood Frataxin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QIDS-C total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Improvement Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in mental status (CHESS score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of participants with positive ANC engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical or microbiologically proven typhoid infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Strength of the distal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR12 (HCV RNA < LLOQ 12 weeks post-treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cerebral cortex thickness and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of intervention to control blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Function assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Had Reactogenicity Events (REs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Significant New Medical Conditions (SNMCs)
Endpoint domain: Adverse events/effects
Primary endpoint: HIV care outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible PCPs who successfully complete randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Event-free Probability of Major or Minor Bleeding Events at 6 and 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Event-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Qualitative mapping of the skin's arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Blood pressure maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vasopressor use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: surgical benefit rate of fluorescent image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Headache Pain Free Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic Stress Disorder Checklist (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in patient-reported tinnitus score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concordance between FFR and IVUS minimum lumen area (MLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Interval Between Infliximab Infusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Average Dose of Infliximab Per Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of meglumine antimoniate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Adverse Event (AE) and Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Hematology Parameters as a Measure of Safety-Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Clinical Chemistry Parameters as a Measure of Safety-Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Quit Attempts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pupil measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Biomarker Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volatile anaesthetics consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perception of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oesophageal circumferential muscle contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oesophageal longitudinal muscle contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oesophageal emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Assessment of oesophageal and LOS distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Dose Required to Achieve Target Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ONSD measurements correlation with intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC (0-4hrs, sGAW after morning dose of medication at day 14)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S100 calcium-binding protein β
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of CD4+CD25+CD127 low T cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence or absence of hospital-acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Sustained Virologic Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Motor Evoked Potential (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Global Rating of Change Scale (GROC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in circulating immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of the CASIA 2 OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the AI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response ratio for all partial seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Virologic success by week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported reduction in HIV risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skillfulness in behaviors for HIV risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ESS change
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Participants With Macroalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Steady state pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects on cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knee KOOS4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine milligram equivalent dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abdominal Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days of Exposure to HGT-1111
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Changes From Baseline in Plasma log10 HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean rates of change in clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-t]) for Ciprofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Ciprofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in lumbar spine bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence rates of HIV
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients having poor sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of subjects with Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steps per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overlay accuracy with 3-dimensional anatomical T1w post contrast scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence in identifying the lesion corresponding areas on cerebral blood volume maps
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cerebral blood volume in small (< 1 cm) enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment during rest and ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Leads Free From Complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary NGF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum tolerated dose of temsirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Columbia University Autobiographical Memory Interview-Short Form (AMI-SF)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anti-pneumococcal antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate of caudate atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Modified Target NAPSI for the Single Most Severely Affected Nail at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Modified Target NAPSI for the Single Most Severely Affected Nail at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Transepidermal water loss measurement (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in IDS-C30 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose determined by dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Attitudes towards clinical trial participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy in treating acute exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very long chain fatty acids (VLCFA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of AL
Endpoint domain: Adverse events/effects
Primary endpoint: residual protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety outcome measure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: Incremental AUC for plasma triacylglycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum Betatrophin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phenotype of CD14 monocytes/osteoclasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in HbA1C from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy and safety of intrapleural alteplase vs urokinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospital days until euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of first attempt intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: weaning rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weaning classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efavirenz Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pattern of osseous MDP uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Convergent validity of Thai version of Urticaria Control Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop-out rate due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of FSGS after renal transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Transanal specimen extraction feasibility
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Cold induced vasodilation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual dexterity-PP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual dexterity-MRM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand and finger temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical Root Fracture Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development profiles of renal dopplers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemorrhage or Recurrent CVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes